Dermatol. praxi. 2018;12(3):134-136 | DOI: 10.36290/der.2018.040
Atopic dermatitis (AD) is chronic inflammatory dermatosis. It is caused by external influences on genetically predisposed skin.The skin barrier dysfunction and immunological imbalance are the most important factors in the pathogenesis of the disease.Emollients, topical corticosteroids, topical immunomodulators and phototherapy are used in the therapy of the mild and moderateform of AD. About 10% of severe cases of AD in adults require systemic therapy which today is represented by cyclosporinA and methotrexat. It is a new therapeutic option dupilumab, human monoclonal antibody against IL4 and IL13. The efficacy andsafety of dupilumab in therapy of AD has been demonstrated in the studies.
Received: March 13, 2017; Accepted: April 19, 2017; Published: October 10, 2018 Show citation